Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has engaged JBN Partners, LLC for a six-month term to enhance public and investor relations, with a total payment of USD$150,000. The company focuses on developing innovative therapeutics for mental health disorders, including PTSD and addiction, using advanced technology and drug development infrastructure. Founded in 2020, Mydecine aims to bridge gaps in mental health treatment with a commitment to responsible development and collaboration with leading experts in the field.
- Engaged JBN Partners to boost investor relations and public awareness.
- Focus on innovative therapeutics for mental health disorders, addressing significant market needs.
- Total payment to JBN Partners is USD$150,000, which could impact short-term cash flow.
VANCOUVER, British Columbia, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that the company has engaged JBN Partners, LLC (“JBN”) to increase public awareness of and interest in the Company, its management and its products by coordinating certain investor relations and corporate financial public relations with members of the investment community, the financial media and the public, in general. The services agreement with JBN has a six-month term with a total payment value of USD
About Mydecine Innovations Group
Mydecine Innovations Group™ (NEO: MYCO) (OTC: MYCOF) (FSE:0NFA) is a biotechnology and digital technology company developing innovative first-and-second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure. Mydecine Innovations Group was founded in 2020 on the guiding principle that there is a significant unmet need and lack of Innovations in the mental health and treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction, and other mental health disorders. Mydecine Innovations Group's business model combines clinical trials and data outcome, technology, scientific and regulatory expertise, focusing on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way we treat mental health disorders. Mydecine Innovations Group's vision is to bridge the current gap between what the cognitive healthcare system currently provides with the needs of the patients. Mydecine Innovations Group is headquartered in Denver, Colorado, USA, with international offices in Leiden, Netherlands.
Learn more at: https://www.mydecine.com and follow the company on Twitter, Instagram, and LinkedIn.
Sign up for Mydecine’s newsletter by scrolling to the bottom of this page.
Sign up for automatic email notifications when Mydecine publishes news here.
For more information, please contact:
Media Contact:
Morgan Kervitsky, Director of Marketing
pr@mydecineinc.com
Investor Relations:
Morgan Kervitsky, Director of Marketing
corp@mydecineinc.com
On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
contact@mydecineinc.com
For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.
This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.
FAQ
What is the latest announcement from Mydecine Innovations Group (MYCOF)?
How much is Mydecine paying JBN Partners for their services?
What is the primary focus of Mydecine Innovations Group?
When was Mydecine Innovations Group founded?
What are some of the mental health issues Mydecine aims to address?
